Trial Profile
Phase IV, Single Arm Study of Safety and Efficacy of Everolimus in Chinese Adults With Tuberous Sclerosis Complex Who Have Renal Angiomyolipoma Not Requiring Immediate Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Sep 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Angiomyolipoma
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 13 Oct 2020 Status changed from active, no longer recruiting to completed.
- 14 Oct 2019 Planned End Date changed from 6 Jan 2022 to 26 Oct 2020.
- 14 Oct 2019 Planned primary completion date changed from 6 Jan 2022 to 26 Oct 2020.